TILT Holdingsの空売り状況は、投資家がTILT Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TILT Holdings (OTC:TLLTF) 株価情報, 空売り情報

TILT Holdings

TILT Holdings Inc is a business solutions provider to the cannabis industry. The company helps cannabis businesses build brands through a portfolio of companies providing technology, hardware, cultivation, and production. The operating segments of the company are Cannabis, Accessories, Corporate, and others. The majority of the revenue is generated from the Accessories segment which is engaged in the manufacturing and distribution of electronic, non-nicotine (i.e., cannabis) devices and systems. The company's geographical segments include the United States, Canada, and others, of which the majority of the revenue is generated from the United States.

TILT Holdings Inc

Financial analyst Tom Lee from Fundstrat Global Advisors provided his analysis on the market&#8217;s response and potential tactics behind the White House&#8217;s actions.
What Happened: On Thursday, in a conversation with StockMKTNewz, Tom Lee gave his viewpoint on the repercussions of the sudden tariff rates declared by the Trump administration. The rates, 46% on Vietnam and 34% on China, were calculated based on trade deficits, a departure from traditional tariff methodologies, and were much harsher than expected.
Lee characterized these rates as &#8220;absurd,&#8221; comparing them to a &#8220;dark comedy&#8221; due to their arbitrary nature and lack of economic rationale. The immediate market reaction was a significant 3.5% opening gap down in the S&amp;P 500, marking the seventh largest negative opening gap in 40 years.
Trump&#8217;s tariff wiped out around $2.5 trillion from the U.S. stock market. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Tom Lee&#039;s BIG Takes After Tariff Liberation Day: Exclusive StockMKTNewz Interview" width="500" height="281" src="https://www.youtube.com/embed/HC6V1B7PceI?start=169&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
As earnings season nears, Lee expects companies with solid fundamentals and limited exposure to tariff-impacted supply chains to stand out as &#8220;superpower companies.&#8221;
Lee believes Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remains stable because the market has already accounted for the worst-case scenario, potentially setting the stage for a V-shaped recovery. Strong performers like Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), and Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), previously MicroStrategy, further indicate that market leaders are stabilizing rather than declining further.
&#8220;I expect a V-shaped recovery, but the timing is now a bit harder to judge because we don't really have the band-aid completely ripped off until April 9th.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/04/44642355/trumps-25-auto-tariffs-spark-stellantis-layoffs-gm-expansion-uaws-shawn-fain-calls-job-cuts-comp" target="_blank" rel="noreferrer noopener">Trump&#8217;s 25% Auto Tariffs Spark Stellantis Layoffs, GM Expansion: UAW&#8217;s Shawn Fain Calls Job Cuts &#8216;Completely Unnecessary&#8217;</a>
Why It Matters: Despite the initial market panic, Lee maintains a cautious optimism, arguing that the economic impact may not be as catastrophic as feared. He pointed out the benefit&nbsp;of falling bond yields: for&nbsp;every 10 basis points the&nbsp;10-year Treasury yield drops, the&nbsp;U.S. saves $36 billion in&nbsp;debt service costs.
Lee sees the White House&#8217;s silence as a calculated strategy to create panic&nbsp;among trading partners, maximizing negotiating&nbsp;leverage until the April 9&nbsp;deadline. He believes this approach is primarily aimed&nbsp;at the EU and China,&nbsp;the two regions most critical&nbsp;to U.S. trade dynamics.
Tom Lee called the market sell-off <a href="https://www.benzinga.com/25/03/44244329/tom-lee-predicts-market-stabilization-following-mondays-overreaction-foresees-may-rate-cut">amid recession fears</a> during mid-March an &#8220;overreaction&#8221;. Even earlier this week, Lee wrote on X, "Markets are deeply oversold," adding that "too many are only pricing in ‘worst case&#8217;" scenarios. 
Despite the market turmoil, Lee encouraged investors to remain resilient,&nbsp;predicting a sharp bounce around&nbsp;April 9 as negotiations progress&nbsp;and the VIX subsides.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/03/44575557/mark-cuban-says-if-they-replaced-elon-musk-with-him-hes-still-try-to-make-government-smaller-by-cutting-a-lot-of-people" target="_blank" rel="noreferrer noopener">Mark Cuban Says, If They Replaced Elon Musk With Him, He&#8217;ll Still Try to Make Government Smaller By &#8216;Cutting A Lot Of People&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Markets

$BTC

MSTR

PLTR

TSLA

Tom Lee Slams Trump's 'Absurd' Tariff Hike — Expects A 'Recovery' But Says Timing Is Uncertain As Market Sheds $2.5 Trillion In A Day

Barclays analyst Manav Patnaik upgrades ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) from Underweight to Equal-Weight and raises the price target from $7 to $9.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades ADT to Equal-Weight, Raises Price Target to $9

TREMFYA&#xAE; demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study
Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA&#xAE; as a first-line treatment option for patients with active psoriatic arthritis
SPRING HOUSE, Pa., April 4, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the TREMFYA&#xAE; (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1

Biotech

General

Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis

EFSH

1847 Holdings Receives Delisting Notice From The NYSE American

<a href="https://www.globenewswire.com/Tracker?data=u9xu6hKY5TP0fcobkUsOApjld7AeQABrgPmRSTxeZLcFwjg1p2BS8Cg6p0_8a92jiN6B2ybQiFVNDVmTSmzxajba4lfFmJdr9whmecoocaY=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group,&nbsp;today announced that it has filed a lawsuit against Peter Ritz and Michael Moe as the controlling officers and directors of LZGI International, Inc ("LZG") under the Racketeer Influenced and Corrupt Organizations Act (RICO), in the United States District Court, Southern District of Florida on March 31, 2025, seeking over $450 million in damages caused by the defendants to Genius Group.
On April 4, 2025, the Company is filing the complaint as part of a Current Report on Form 6-K with the SEC, and as part of a police report to the Commercial Affairs Department of the Singapore Police Force for organized criminal activity against a Singapore public company. The Company has also notified: The Securities and Exchange Commission (SEC); The Criminal Division, Fraud Section, Department of Justice (DOJ); and the Corporate Fraud Division, Federal Bureau of Investigation (FBI) on the contents of the RICO complaint with a request for them to pursue their own actions.
The RICO Complaint includes the following:
<ul>
<li>A scheme by the Defendants to defraud LZGI and Genius Group shareholders through a pattern of mail fraud, wire fraud, and extortion, to acquire control of different microcap entities, enrich themselves through the diversion of funds and thereby render LZGI and its subsidiaries insolvent. &nbsp;</li>
<li>A scheme by the Defendants to use LZGI as a vehicle to coerce and extort the insiders of microcap companies for the purpose of taking over the business and looting the assets of the entities, with Genius Group being their latest victim. &nbsp;</li>
<li>The Defendant's attempts to defraud Genius Group through various acts of mail fraud, wire fraud and extortion, including the fraudulent inducement to enter an asset purchase agreement based on false representations and warranties in order to extract funds from Genius Group for a purported asset that was never in their ownership control, and when that failed, an attempt to take control of the Company through an illegally executed Boardroom coup. &nbsp;</li>
<li>A recently recorded meeting between Ritz and Genius executives, during which Ritz detailed his latest scheme of weaponizing the US legal process to obtain a temporary restraining order and preliminary injunction preventing Genius Group from issuing shares and raising funds to continue operations. Having obtained a court ordered ban through false and misleading statements, Ritz has threatened that if the Company does not give him millions more to fund his next scheme to defraud LZGI and Genius Group shareholders, he could bankrupt LZGI to ensure Genius Group receives nothing from the arbitration, while it remains tied up in restrictions. By this scheme, Ritz gave Genius Group the choice of aiding their fraud or face the threat of forced closure. &nbsp;</li>
<li>Genius Group has demanded a trial by jury and seeks a verdict and judgement awarding the Company no less than $150 million in monetary damages, which based on treble damages pursuant to 772.104(1), Fla. Stat. (2024) is minimum of $450 million in damages. &nbsp;</li>
</ul>
The Company is represented in the RICO complaint by the Basile Law Firm P.C., a specialist in securities violations and RICO claims. The case number is 1:25-cv-21496.
The RICO complaint is one of a series of legal measures that the Company is currently taking against fraud and market manipulation. It is separate from the lawsuit led by Christian Attar related to alleged naked short selling and spoofing of Genius Group's shares, with alleged damages previously calculated at between $251 million and $263 million. Wes Christian of Christian Attar anticipates calculations on updated damages will be completed and the complaint will be filed within the next thirty days.

Legal

Genius Group Sues LZGI International's Peter Ritz And Michael Moe Under RICO Act In Southern District Of Florida, Seeking Over $450M In Damages For Alleged Wrongdoing

Barclays analyst Manav Patnaik downgrades UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) from Equal-Weight to Underweight and lowers the price target from $180 to $152.

Downgrades

Barclays Downgrades UniFirst to Underweight, Lowers Price Target to $152

<h3>Gainers</h3>
<ul>
<li>PAMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAMT#NASDAQ">PAMT</a>) shares increased by 25.8% to $13.98 during Friday's pre-market session. The company's market cap stands at $304.5 million. </li>
<li>Advent Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares rose 18.06% to $3.66. The market value of their outstanding shares is at $9.6 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares moved upwards by 16.99% to $0.35. The company's market cap stands at $50.1 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock increased by 16.27% to $0.5. The company's market cap stands at $6.3 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) shares increased by 15.25% to $0.49. The company's market cap stands at $47.2 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock moved upwards by 12.62% to $4.46. The market value of their outstanding shares is at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) shares declined by 32.3% to $2.01 during Friday's pre-market session. The market value of their outstanding shares is at $108.4 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares fell 21.61% to $0.18. The market value of their outstanding shares is at $35.6 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares declined by 12.39% to $0.92. The market value of their outstanding shares is at $23.4 million. </li>
<li>ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) stock declined by 12.35% to $40.39. The company's market cap stands at $6.5 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AREB

EHGO

EXLS

LNZA

PAMT

SCWO

SLND

UGRO

10 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares rose 39.2% to $0.11 during Friday's pre-market session. </li>
<li>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock increased by 11.48% to $0.3. The company's market cap stands at $32.9 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares moved upwards by 10.7% to $0.48. The market value of their outstanding shares is at $4.7 million. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares increased by 8.12% to $6.39. The market value of their outstanding shares is at $1.2 billion. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Newton Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) stock moved upwards by 8.1% to $1.6. </li>
<li>Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) shares increased by 8.0% to $34.54. The company's market cap stands at $3.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock fell 27.5% to $2.0 during Friday's pre-market session. The market value of their outstanding shares is at $22.0 million. </li>
<li>Youdao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) shares declined by 18.33% to $6.33. The company's market cap stands at $756.5 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) shares declined by 17.57% to $0.26. The company's market cap stands at $3.9 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares decreased by 17.47% to $4.3. The market value of their outstanding shares is at $219.7 million. </li>
<li>Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) stock decreased by 16.44% to $3.0. The market value of their outstanding shares is at $115.0 million. </li>
<li>Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) stock declined by 16.24% to $3.2. The market value of their outstanding shares is at $248.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLAR

GORV

JZXN

MULN

NWTG

SHCO

TCTM

VEEE

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 80.6% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $9.6 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares rose 25.15% to $1.84. The market value of their outstanding shares is at $1.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock moved upwards by 23.77% to $0.54. The market value of their outstanding shares is at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares moved upwards by 23.73% to $0.77. The market value of their outstanding shares is at $173.0 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 14.89% to $1.08. The company's market cap stands at $14.7 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 12.06% to $0.68. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares declined by 57.2% to $1.01 during Friday's pre-market session. The company's market cap stands at $46.4 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock fell 41.28% to $0.51. The market value of their outstanding shares is at $15.5 million. </li>
<li>XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shares decreased by 35.09% to $16.71. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 30.39% to $1.26. The market value of their outstanding shares is at $16.7 million. </li>
<li>Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) shares decreased by 23.34% to $13.01. The company's market cap stands at $417.9 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock fell 22.75% to $7.2. The market value of their outstanding shares is at $315.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DNTH

ENTO

KAPA

KRMD

MAZE

NMTC

SGMO

XOMAP

ZVSA

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) stock moved upwards by 40.8% to $0.27 during Friday's pre-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) stock rose 31.38% to $1.06. The company's market cap stands at $19.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares moved upwards by 30.48% to $4.35. The company's market cap stands at $5.0 million. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock increased by 13.9% to $0.17. The market value of their outstanding shares is at $1.4 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock increased by 12.66% to $0.34. The market value of their outstanding shares is at $13.9 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock increased by 10.41% to $0.82. The company's market cap stands at $14.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) shares decreased by 16.6% to $3.15 during Friday's pre-market session. The company's market cap stands at $290.3 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock fell 16.44% to $1.83. The company's market cap stands at $110.4 million. </li>
<li>Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares fell 15.87% to $7.16. The company's market cap stands at $733.4 million. </li>
<li>Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) shares decreased by 15.79% to $2.88. The company's market cap stands at $20.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) shares declined by 12.69% to $6.4. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares fell 12.4% to $0.43. The company's market cap stands at $4.5 million. The company's, Q4 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARLO

BNAI

BTOG

CXAI

DTST

OBLG

SLNH

SMSI

VNET

12 Information Technology Stocks Moving In Friday's Pre-Market Session

OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO's common stock has been repurchased under the existing program since its authorization in July 2024.

Buybacks

OPKO Health Announces $100M Increase To Its Existing Share Repurchase Program, Bringing The Aggregate Capacity Of The Program To $200M

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $23 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $23 Price Target

Stock Split

Twin Vee PowerCats Announces 1-For-10 Reverse Stock Split, Effective April 7,2025

Commercial Vehicle Group, Inc. (the "Company" or "CVG") announced the retirement of Robert C. Griffin, from the Board of Directors of the Company, effective May 15, 2025, without standing for re-election at the 2025 annual meeting of stockholders.
Mr. Griffin has served as a Director since 2005 and is the current Chairman of the Board. Mr. Griffin's retirement is not as a result of any disagreement with the Company, its management, the Board or any committee of the Board. It is expected that William C. Johnson will serve as the Chairman of the Board following Mr. Griffin's retirement.

Management

CVGI

Commercial Vehicle Group Board Member Robert Griffin To Retire; William Johnson To Become Chairman Of The Board

Barclays analyst Manav Patnaik downgrades Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) from Overweight to Equal-Weight and lowers the price target from $325 to $260.

Barclays Downgrades Equifax to Equal-Weight, Lowers Price Target to $260

Mike Hansen to Retire as CFO at Fiscal Year-End
Scott Garula to Succeed Hansen as CFO
Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) today announced that Mike Hansen will retire from his role as Executive Vice President &amp; Chief Financial Officer (CFO) and transition to a new role as Assistant to the CEO, effective May 31, 2025. In this capacity, Hansen will support the transition to his successor and contribute to certain strategic initiatives and special projects. Scott Garula, currently President of Cintas' Rental Division, will succeed Hansen as Executive Vice President &amp; CFO.
Todd Schneider, Cintas President &amp; CEO, said, "Continuity of leadership is important, and this planned transition follows a thoughtful succession process. We have a tremendous bench of world-class leaders ensuring the right team is in place to guide our Company into the future.

CTAS

Cintas' Mike Hansen To Retire As CFO At Fiscal Year-End; Scott Garula To Succeed Hansen As CFO

Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)&nbsp;announced Thursday that it will offer new and existing customers a three-year price lock guarantee on all myPlan and <a target="_blank" href="https://www.benzinga.com/topic/verizon" rel="noreferrer noopener">myHome network plans</a>.
The deal builds on Verizon&#8217;s MyPlan and MyHome offerings, which allow customers to bundle streaming services, mobile phone service and home internet, including <a href="https://www.verizon.com/about/news/accelerating-customer-first-strategy-3-year-price-lock-and-free-phone" target="_blank" rel="noreferrer noopener">devices</a>.
Verizon previously offered free phones for its premium subscriber plans.&nbsp;Now, it is offering a free phone to new and existing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/02/43883822/t-mobile-wins-nyc-public-safety-deal-introduces-new-plans-for-first-responders-and-military-families" rel="noreferrer noopener">T-Mobile Wins NYC Public Safety Deal, Introduces New Plans For First Responders And Military Families</a>
The users will need to trade in an old Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), or Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google phone in any condition and be on a myPlan subscription.&nbsp;
Verizon Consumer CEO Sowmyanarayan Sampath said the three-year price lock across mobile and home provides peace of mind and a free phone on every myPlan, gives customers even more value.
The company will also offer free satellite-based text messaging to any myPlan subscriber on qualifying devices.
However, the three-year guarantee does not encompass fees and taxes, implying Verizon can still raise the monthly bill through increased fees,  cut the monthly autopay discount, or persuade consumers to migrate to a pricier plan with the offer of a new phone, The Verge <a href="https://www.theverge.com/news/642325/verizon-myplan-price-lock-three-years" target="_blank" rel="noreferrer noopener">reports</a>. 
Verizon and its peers&nbsp;AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)&nbsp;and&nbsp;T-Mobile US Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) compete intensely for market share.
Since Sampath&nbsp;assumed charge in 2023, he has&nbsp;hiked prices&nbsp;and introduced flexible pricing plans to drive growth, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-03/verizon-offers-new-perks-to-woo-subscribers-in-tight-market?sref=TBDibEcD" rel="noreferrer noopener">reports</a>. Verizon has also added bundles that include access to <a target="_blank" href="https://www.benzinga.com/news/23/12/36071567/verizon-unveils-groundbreaking-10-streaming-deal-netflix-max-join-forces" rel="noreferrer noopener">streaming services such</a> as Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
T-Mobile&nbsp;<a target="_blank" href="https://www.benzinga.com/tech/25/02/43582884/elon-musks-spacex-and-t-mobile-go-live-with-starlink-powered-satellite-to-cell-service-heres-how-much-it-will-cost" rel="noreferrer noopener">plans to charge&nbsp;customers</a> $10-$15 monthly for SpaceX&#8217;s Starlink-supported text and data services.
Price Action: VZ stock is up 0.59% at $45.89 premarket on the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44639271/nvidias-custom-gpu-enhances-nintendo-switch-2-with-ai-features-real-time-ray-tracing-4k-support" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Custom GPU Enhances Nintendo Switch 2 With AI Features, Real-Time Ray Tracing, 4K Support</a></li>
</ul>
Photo: Shutterstock

Media

AAPL

GOOG

GOOGL

NFLX

SSNLF

TMUS

Verizon's New 3-Year Price Lock, Free Phone Offer: Strategic Move To Boost Customer Retention

In the preceding three months, 4 analysts have released ratings for G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.25, a high estimate of $32.00, and a low estimate of $25.00. A 12.69% drop is evident in the current average compared to the previous average price target of $33.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768074_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive G-III Apparel Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$25.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to G-III Apparel Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of G-III Apparel Group compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of G-III Apparel Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into G-III Apparel Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GIII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on G-III Apparel Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About G-III Apparel Group</h2>
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.
<h3>Breaking Down G-III Apparel Group's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining G-III Apparel Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.77% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: G-III Apparel Group's net margin excels beyond industry benchmarks, reaching 5.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): G-III Apparel Group's ROE stands out, surpassing industry averages. With an impressive ROE of 2.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): G-III Apparel Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GIII

A Glimpse Into The Expert Outlook On G-III Apparel Group Through 4 Analysts

Across the recent three months, 6 analysts have shared their insights on AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $25.00, and a low estimate of $14.00. Observing a downward trend, the current average is 6.47% lower than the prior average price target of $23.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768066_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of AVITA Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AVITA Medical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AVITA Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AVITA Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AVITA Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering AVITA Medical: A Closer Look</h2>
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
<h3>Understanding the Numbers: AVITA Medical's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, AVITA Medical showcased positive performance, achieving a revenue growth rate of 29.67% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AVITA Medical's net margin excels beyond industry benchmarks, reaching -62.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AVITA Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -138.57%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: AVITA Medical's debt-to-equity ratio is notably higher than the industry average. With a ratio of 10.22, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCEL

6 Analysts Assess AVITA Medical: What You Need To Know

Throughout the last three months, 4 analysts have evaluated Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Orchestra BioMed Hldgs, revealing an average target of $14.5, a high estimate of $20.00, and a low estimate of $12.00. Experiencing a 9.38% decline, the current average is now lower than the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768055_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Orchestra BioMed Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Orchestra BioMed Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Orchestra BioMed Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Orchestra BioMed Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Orchestra BioMed Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OBIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Orchestra BioMed Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Orchestra BioMed Hldgs</h2>
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
<h3>A Deep Dive into Orchestra BioMed Hldgs's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Orchestra BioMed Hldgs faced challenges, resulting in a decline of approximately -3.44% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Orchestra BioMed Hldgs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6385.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Orchestra BioMed Hldgs's ROE excels beyond industry benchmarks, reaching -40.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Orchestra BioMed Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.33%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Orchestra BioMed Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Where Orchestra BioMed Hldgs Stands With Analysts

Earnings

Press Releases

TILT Holdings Reports Second Quarter 2024 Results

TILT Holdings Announces Board Changes

Commonwealth Alternative Care Aims High for Fall Community Engagement

TILT Holdings Announces the Departure of its Chief Revenue Officer

TILT Sets Third Quarter 2024 Conference Call for November 14 at 5:00 p.m. ET

TILT Holdings Reports Third Quarter 2024 Results and Announces Strategic Review of its Plant-Touching Business

Contracts

TILT Holdings Signs Definitive Agreement to Divest Retail Locations in Massachusetts to In Good Health for $2 Million

TILT Sets Fourth Quarter and Full Year 2024 Conference Call for March 19 at 5:00 p.m. ET

TILT Holdings Reports Fourth Quarter and Full Year 2024 Results

TILT Holdings Receives Default Notice from Innovative Industrial Properties

TLLTF

Comments

TILT Holdings

空売り

TILT Holdings (OTC:TLLTF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル